Fundraising Fox
🦊/Companies
Sign in

Sequella

Rockville, US · Delaware corporation

Find your way into Sequella

Sequella is a clinical-stage pharmaceutical company developing antibiotics to treat drug-resistant bacterial, fungal, and parasitic infections, including tuberculosis, MDR-TB, XDR-TB, H. pylori, and C. difficile. Its pipeline includes drug candidates such as SQ109 and sutezolid, which have completed phase 2 clinical trials.

BiotechHealthtech

Founders & leadership

CACarol A. Nacy
Carol A. NacyinFounder
LM
Lawrence MillerExecutive
LE
Leo EinckExecutive

Board

BR
Bradley RotterBoard director
PM
Paige MacDonaldBoard director
JF
John FriedmanBoard director
RI
Ronald I. MeltzerBoard director
KL
Kenneth LynnBoard director

Reported raises · per SEC filings

Form D private placements

$6.4M disclosed across 4 rounds · 2014–2017

▶$630.6KraisedOct 2017 · 6 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • MARK RAMPYExecutive Officer
  • LAWRENCE MILLERExecutive Officer
  • RONALD I. MELTZERDirector
  • CAROL A. NACYExecutive Officer, Director
  • DAVID MCNEELEYExecutive Officer
  • LEO EINCKExecutive Officer, Director
  • BRADLEY ROTTERDirector
  • JOHN FRIEDMANDirector
  • PAIGE MACDONALDDirector
Offering amount
$3.6M
Amount sold
$630.6K
Minimum investment
$25.1K
Sales commissions
$42.8K
Proceeds to insiders
$317K
Placement agents
DAVID N. OLSON
First sale
Sep 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.7MraisedSep 2016 · 9 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • BRADLEY ROTTERDirector
  • JOHN FRIEDMANDirector
  • RONALD I. MELTZERDirector
  • LAWRENCE MILLERExecutive Officer
  • PAIGE MACDONALDDirector
  • LEO EINCKExecutive Officer, Director
  • CAROL A. NACYExecutive Officer, Director
Offering amount
$3M
Amount sold
$1.7M
Minimum investment
$25K
Sales commissions
$15K
Placement agents
DAVID N. OLSON
First sale
Aug 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$940.9KraisedSep 2016 · 9 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Lawrence MillerExecutive Officer
  • Bradley RotterDirector
  • Leo EinckExecutive Officer, Director
  • Paige MacDonaldDirector
  • John FriedmanDirector
  • Ronald I. MeltzerDirector
  • Carol A. NacyExecutive Officer, Director
Offering amount
$940.9K
Amount sold
$940.9K
First sale
Aug 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.1MraisedOct 2014 · 36 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Carol A. NacyExecutive Officer
  • Leo EinckExecutive Officer
  • Lawrence MillerExecutive Officer
  • Ronald I. MeltzerDirector
  • Paige MacDonaldDirector
  • John FriedmanDirector
  • Kenneth LynnDirector
  • Bradley RotterDirector
Offering amount
$3.1M
Amount sold
$3.1M
Minimum investment
$25K
Sales commissions
$339K
Placement agents
Paulson Investments
First sale
Sep 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 25 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
NASAPhase I2018$125K
National Institutes of Health (NIH)National Institutes of HealthPhase I2012$565.3K
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2011$587.9K
National Institutes of Health (NIH)National Institutes of HealthPhase I2010$599.8K
National Institutes of Health (NIH)National Institutes of HealthPhase I2009$594.7K
National Institutes of Health (NIH)National Institutes of HealthPhase I2009$305.1K
National Institutes of Health (NIH)National Institutes of HealthPhase II2008$2.3M
National Institutes of Health (NIH)National Institutes of HealthPhase I2008$244.3K
National Institutes of Health (NIH)National Institutes of HealthPhase I2006$228K
National Institutes of Health (NIH)National Institutes of HealthPhase I2004$299.5K
National Institutes of Health (NIH)National Institutes of HealthPhase II2003$2M
National Institutes of Health (NIH)National Institutes of HealthPhase II2003$939.1K
National Institutes of Health (NIH)National Institutes of HealthPhase I2003$299K
National Institutes of Health (NIH)National Institutes of HealthPhase I2003—
National Institutes of Health (NIH)National Institutes of HealthPhase I2003—
National Institutes of Health (NIH)National Institutes of HealthPhase II2002$1.1M
National Institutes of Health (NIH)National Institutes of HealthPhase I2002$99.9K
National Institutes of Health (NIH)National Institutes of HealthPhase I2002—
National Institutes of Health (NIH)National Institutes of HealthPhase I2001$300K
National Institutes of Health (NIH)National Institutes of HealthPhase I2001$294.9K
National Institutes of Health (NIH)National Institutes of HealthPhase I2001$232K
National Institutes of Health (NIH)National Institutes of HealthPhase I2001$162.2K
National Institutes of Health (NIH)National Institutes of HealthPhase I2000$300K
Department of Health and Human ServicesPhase I1999$294.2K
Department of Health and Human ServicesPhase I1998$100K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Maryland biotech Sequella on hunt for $20M for drug trials - Washington Business Journal - BioHealth Innovationbiohealthinnovation.org · Mar 2013Sequella Awarded $4.6 million in New NIH Grants to Expand Anti-Infectives Pipeline | Fierce Biotechfiercebiotech.com · Apr 2011Sequella, Inc. Obtains Funding to Continue Expansion of its Anti-infectives Pipeline - BioSpacebiospace.com · Oct 2009Sequella, Inc. Receives American Recovery and Reinvestment Funding Through the National Institutes of Health (NIH) Grant Funds to Finalize Synthetic Manufacturing Process for Promising New TB Drug Candidate - BioSpacebiospace.com · Oct 2009Sequella Receives SBIR Funding Grant from the NIH for Further Development of Tuberculosis Drug SQ609 | Fierce Biotechfiercebiotech.com · Feb 2009

Frequently asked questions

What does Sequella do?
Sequella is a clinical-stage pharmaceutical company developing antibiotics to treat drug-resistant bacterial, fungal, and parasitic infections, including tuberculosis, MDR-TB, XDR-TB, H. pylori, and C. difficile. Its pipeline includes drug candidates such as SQ109 and sutezolid, which have completed phase 2 clinical trials.
Who founded Sequella?
Sequella was founded by Carol A. Nacy.
How much funding has Sequella raised?
Sequella has disclosed $6.4M raised across 4 rounds.
Where is Sequella headquartered?
Sequella is headquartered in Rockville, US.